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Access to orphan drugs (In EU regulation Orphan Drugs are refered as Orphan Medi-
cinal Products (OMP)) is a key role in determining whether patients with rare diseases (RDs) will 
receive adequate and efficient treatment. The objective of this article is to identify differences in 
patient access to orphan drugs in 3 pharmaceutical markets: Serbia, Croatia and Macedonia. 
Patient access was defined: as the market access (availability) and affordability (financial 
accessibility). We analysed the legislative requirements for the authorisation process and made 
a cross country comparison. Retrospective cross-sectional analysis was done on drug lists in 
selected countries and a cross-comparison between the List of Orphan Drugs in Europe (LODE) 
for a six-month period (May 2014-October 2014). We included all 179 OMPs marketed in EU in 
our analysis, which had received market authorization in Croatia upon its membership in the 
EU. Total number of marketed drugs in Serbia was 59 (32.96%) drugs and in Macedonia 52 
(29.05%) drugs. However, market authorization does not guarantee patient access to any 
given drug, so only 39.11% of OMPs could be accessed by Croatian patients (70 drugs).The 
number of refunded drugs in Serbia and Macedonia was smaller (32 and 20, respectively) 
which makes respectively, 17.88% and 11.17% of drugs on the LODE. The present study 
showed some variations between countries in selected indicators of availability and access to 
orphan drugs. Patients in Croatia had greater number of registered and refunded drugs, but in 
Serbia more than a half of registered OMPs could be refunded from National Health Insurance 
Fund. Macedonia had smaller number of inhabitants and also had the smaller number of 
patients from certain RDs which results in lower total number of OMPs.  
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Introduction 
 
According to the Regulation on Orphan Medici-
nal Products of the European Parliament and the Eu-
ropean Council (EC) N° 141/2000 Orphan Medicinal 
Products (OMPs, also known as Orphan drugs-ODs1) 
are used for the diagnosis, treatment and prevention 
of rare diseases (RDs) occurring with a prevalence of 
at least 0.05%, i.e. affecting no more than 5 in 
10,000 people (1). In Europe, the status of rare di-
seases may refer to all diseases without a specific 
treatment while in the USA, regardless of their pre-
valence, rare diseases include those without a pro-
ven efficient treatment with existing drugs. In both 
regions of the world, a two-step licensing system is 
applied by regulatory bodies to market drugs inclu-
ding orphan designation (OD) and marketing autho-
risation (MA) for an OMP. RD are characterised not 
only by their low prevalence but also by the fact that 
the rarity concept can be considered from several as-
pects (2): the perspective of the centre of expertise 
(clinical centres of excellence), a diagnostic reference 
centre, clinical studies, as shown in Figure 1.  
 
 
 
                                                 
1 We shall use interchangeable the terms Orphan Medicinal Products 
(OMPs) and orphan drugs (ODs) in this text. 
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Figure 1. Rarity concept 
 
 
 
The process of obtaining OD includes the cen-
tralized procedure of the EU or national procedures 
for countries that are not EU members. There is a 
special Committee for Orphan Medicinal Products 
(COMP) within EMA whose task is to control criteria 
connected to the significant benefit for acquiring or-
phan status and to the guidelines for clinical rese-
arch in small groups which are used for assessment 
of clinical proof, while acquiring permission (3).  
Besides classical drugs for rare diseases which 
passed the complete procedure for getting the OD 
and marketing authorisation (MA) EMA recognises 
additional group of OMPs, without OD and with MA. 
This group of drugs includes all those drugs which 
possess drug permission for use with one or more 
indications for rare diseases, but did not pass the 
procedure for acquiring OD, or the status was re-
moved. OMPs with MA and without OD cannot be of 
the same name like the name dedicated to other 
indications. 
 
Aim 
 
This paper aimed to evaluate the market ac-
cess (availability) to OMPs and make a comparison 
in three neighbouring countries (Serbia, Macedonia 
and Croatia) with regulatory approach. A further aim 
was tto evaluate affordability (financial accessibility) 
of OMP in selected coutries. 
 
Material and methods 
 
The following methods were used: a compa-
rative analysis of applications for MA of drugs in 
Serbia, Macedonia, and Croatia. Serbia and Macedo-
nia are non-Eu countries and Croatia is EU country 
with EU/EMA procedures accepted. The manual do-
cument analysis of secondary data was conducted 
on October 2014, comparing the national legislative 
files with the Regulation on OMP (Regulation (EC) 
no. 141/2000. Furthermore, in order to study poten-
tial differences between OMP availability and afford-
ability in Serbia, Macedonia and Croatia, we perfor-
med a comparative study of the authorised OMP and 
OMP included in the reimbursement drug lists in the 
selected countries. 
First, we obtained information about the OMPs 
with MA in Europe from the List of Orphan Drugs in 
EU (LODE) for a six-month period (May 2014-Oc-
tober 2014), including OMP with and without prior 
OD (4). Then, we searched the officially issued so-
urces for authorised drugs and reimbursed drugs in 
the three countries. Information on the OMP avail-
ability in these countries was systematized by INN 
and ATC code from the databases of the national 
authorities for National drug registers (NDRs) and 
National Reimbursement Lists (NRLs). The market 
access of OMPs was analyzed by crossing OMPs ide-
ntified in the NDRs and LODE; the affordability was 
evaluated by crossing NRLs with LODE among the 
three countries.  
The data were collected from the NDRs in Ser-
bia, Macedonia and Croatia. The data of reimbursed 
OMP were collected from the NRLs in selected coun-
tries.  
The sources of documents were collected from 
the official website of the Medicines and Medical De-
vices Agency of Serbia (MMDAS) and from the Na-
tional Health Insurance Fund (NHIF) of the Republic 
of Serbia (5, 6), from the official website of the Minis-
try of Health, and NHIF of the Republic of Macedonia 
(7) and from the official website of the Medicines 
and Medical Devices Agency of Croatia (MMDAC) 
and NHIF of Croatia (8, 9). 
 
Results 
 
The results connected with the regulatory ava-
ilability refer to the analysis of legislative approa-
ches for the acquiring and renewal of the MA, in the 
sense of time limits for procedures and types of MA 
procedures. The availability analysis refers to the re-
gistered drugs authorised at national drug lists, while 
the analysis refers to reimbursed drugs, meaning  
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financial affordability of the drugs in the selected co-
untries. All the results are given for each country as 
follows (Serbia, Macedonia and Croatia) and then 
the comparison between them was made.  
 
Analysis of the legislative and policies to OMP 
in the selected countries  
 
All three selected countries define similar re-
gulatory requirements for the MA of OMP. The ana-
lysis of the application for MA will be presented in 
the following sections whereas the comparison of 
the results obtained in the selected countries is pre-
sented in Table 1. 
 
Serbia - regulatory approach 
 
According to the National Organization for Rare 
Diseases of Serbia (NORDS), about 500.000 people 
are suffering from some of the RD out of 7.2 million 
of inhabitants in Serbia (10). In the Republic of Ser-
bia, the MA of OMP is included in the national pro-
cedure for MA of all medicinal products. A drug is 
launched onto the market with a predetermined in-
tensity of effect, pharmaceutical form and package 
based on a drug licence issued by the MMDAS which 
confirms that all the regulatory requirements for MA 
have been fulfilled and that a drug fulfils the stan-
dards of high quality, safety and efficiency. More-
over, the latest amendments introduced by the phar-
maceutical legislature in the Republic of Serbia in 
2010, taken over from the European directives on 
medicines, pertain directly and indirectly to OMPs: i) 
a new definition of drugs was introduced so as to 
include all the progressive forms of therapy, gene or 
cell therapy, ii) the drug licence is to be renewed 
after five years after which period it is issued for an 
indefinite period of time, iii) a new period for data 
protection related to the results of pre-clinical and 
clinical studies, the so called "8+2+1" period (data 
exclusivity period), was introduced by a new directi-
ve, iv) the introduction of new categories for drug 
marketing authorisation and licensing accelerated ap-
proval licence is to be granted within 150 days after 
receiving the complete application (Table 1.). A con-
ditional approval may be granted for drugs used for 
the treatment, prevention or diagnosis of RDs and 
for drugs already licensed under a centralised proce-
dure as well as other drugs of great importance for 
public health. Upon agreement with an applicant, 
MMDAS may issue a drug licence under certain con-
ditions, which the applicant is expected to fulfil and 
which are revised and checked by MMDAS once in 
12 months following the date the adaptive licence 
was issued. The licence is valid for 12 months and 
may be renewed until the necessary requirements 
for a proper licence are fulfilled in case the benefits 
of the drug in question surpass the risks that may 
occur due to insufficient data on a clinical research. 
An adaptive licence may be issued under an accele-
rated procedure. 
 
 
 
Macedonia - regulatory approach 
 
It is estimated that in Macedonia from 2.1 mil-
lion people, there are about 100.000 patients suffer-
ing from RDs. The Macedonian Law on Medicines and 
Medical Devices governs the use of medicines and 
medical devices in human medicine, their quality, 
safety and effectiveness, their production, testing, 
marketing, sale, prices, quality control, advertising 
and inspection supervision (11). The Medicines and 
Medical Devices Agency of Macedonia (MMDAM) is-
sues approvals for drugs authorised in at least three 
EU countries within 15 days after a complete appli-
cation was submitted on the basis of their quality, 
safety and effectiveness estimated in the procedure 
of MA in the EU and upon the proposal of the Com-
mittee for Medicines. In case of submitting an appli-
cation for a drug authorised in fewer than three EU 
countries, the MMDAM either accepts or rejects the 
application within 90 days after the application was 
submitted on the basis of the drug’s quality, safety 
and effectiveness estimated in the MA in the EU and 
upon the proposal of the Committee for Medicines. 
MA is granted for a period of eight years. 
An adaptive licence is granted by the Agency 
in case the drug in question is unavailable, yet es-
sential for a patient’s welfare and treatment (rare di-
seases, ethical aspects, life-threatening diseases). An 
adaptive licence is granted for one year at most 
(12).  
 
Croatia - regulatory approach 
 
It is estimated that in Croatia there are about 
250.000 patients suffering from RDs (4.2 million 
populations) The Republic of Croatia placed OMPs on 
the "List of exceptionally expensive drugs" in 2006. 
OMPs include all drugs that pursuant to regulations 
in the European Union have been granted the status 
of drugs used for the treatment of serious and rare 
diseases. Since 2010, Medicines and Medical Devices 
of Croatia (MMDAC) has been publicising a list of 
OMPs with MA and OD in the EU and which have 
been granted a European marketing authorisation 
(EMA) (13). In accordance with the Law on Medici-
nes, OMP include all drugs that pursuant to EU re-
gulations have been granted the status of drugs us-
ed for the treatment of serious and rare diseases 
(13). Since 2010, the MMDAC has been posting on 
its Internet pages a list of OMPs with an OD in the 
EU and MA (13). The Managing Board of the Croa-
tian Health Insurance Fund determines which drug is 
to be placed on the "List of exceptionally expensive 
drugs" after deliberation by the Committee for Medi-
cines. The financing of treatment by a drug from the 
"List of expensive drugs" is financed by a separate 
fund part of the state budget allocated to expensive 
drugs under supervision paying particular attention 
to the control of drugs use increase. Compassionate 
use of drugs is also possible from the moment of 
diagnosis until the drug is authorised for use. OMPs 
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availability depends on import procedures and treat-
ment financing. Drugs which are not on the "List of 
expensive drugs" are financed by hospital funds, 
which might impose a significant financial burden 
upon an institution. Table 1 shows legislation and 
policies in the area of rare diseases and orphan drugs 
in Serbia, Macedonia and Croatia.  
 
 
 
Table 1. Legislation and policy in the area of rare diseases and orphan drugs in Serbia, Macedonia and Croatia 
 
 
 Serbia Macedonia Croatia 
Population (mill) 
GDP per capita in 2014 (Euro) 
7.2 
3772 
2.11 
2642 
4.3 
9620 
Number of patients with rare 
diseases 
500.000 100.000 250.000 
Key incentives of the orphan drug legislation 
The time limit for the valid 
application for MA (days) 
210 210 210 
The time limit for the reduced 
application for MA (days) 
150 
15 days if MP is avaliable in 3 
countries in EU 
90 days if MP is avaliable in < 3 
countries in EU 
150 
Orphan Drug MA (years) 
Normal approvals 
5 5 5 
Orphan Drug MA (years) 
Conditional approvals 
1 1 1 
Orphan Drug MA (years) 
Exeptional circumstances 
/ / 1 
 
 
 
 
Analysis of market access of OMPs in the 
selected countries 
 
In October 2014, 78 orphan drugs were on 
the LODE in Europe with OD and with MA in the EU 
and 101 drugs with MA and without OD (14).  
In Serbia, 32.96% of OMPs were on the 
LODE, while 29.05% of all drugs in Macedonia were 
on the LODE (Graph 1.). All 179 registered drugs on 
the LODE became available in the Republic of Croa-
tia upon its membership in the EU (October 2014).  
 
 
 
 
 
Graph 1. Total number of OMPs in the selected countries (October 2014) 
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Analysis of affordability of OMPs in the 
selected countries 
 
Serbia - affordability 
 
The amendments to the Law on health insu-
rance created legal grounds for providing distinct 
funds in the Serbian budget for financing the treat-
ment of RD (15). The financial plans for patients were 
first drafted in 2012 on which occasion a separate 
fund was established. The fund is supposed to finan-
ce medical expenses caused by the treatment of RD 
with drugs not included in the NRLs. The financing of 
the fund is regulated by the Law of Health Insurance 
and the Law of Games of Chance so that 5% of the 
budget income is allocated to financing treatment of 
RD (15, 16). An amount of 335,322000 RSD (corre-
sponding to about 2,733,781 EUR) was anticipated 
by the amendments to the financial plan for year 
2014 to be transferred to the National Fund from the 
budget of Serbia intended for health protection and 
treatment RD patients (17). In Serbia, OMPs are on 
one of the five Lists of drugs of the National Health 
Insurance Fund of the Republic of Serbia (NHIFRS) 
(A, A1, B, C, D) and are subject to either complete 
or partial reimbursement. The Government of Serbia, 
on the 30th August 2014, founded the Budget fund 
for treatment and conditions or injures that could 
not be successfully treated in Serbia. The Fund is in-
tended for the treatment of children up to 18 years 
suffering from RDs that are curable abroad if it is not 
possible to diagnose them in Serbia. The Fund is open 
in an indefinite period and managed by the Ministry 
of Health (18).  
 
Macedonia - affordability 
 
In Macedonia, OMPs are financed by funds 
from the budget of Macedonia. At the beginning of 
every year, the Government adopts the Programme 
for the treatment of RDs in the Macedonia defining 
how much money from that year’s budget is alloca-
ted to this purpose and how it will be spent (19). 
The government of Macedonia adopts the Program-
me for the treatment of RDs pursuant to the Law of 
Health Insurance every year. In 2014, the Program-
me was financed with 80,000,000 MKD (correspond-
ing to about 1,331,412 EUR). The newest amend-
ments to the Law of Excise and the Law of Health 
Insurance adopted in December 2014 determined 
that an amount of 0053 MKD per cigarette pack was 
to be used for the financing of rare diseases, which 
is an extra amount of 250,000,000 MKD annually 
(corresponding to about 4,160,662 EUR). OMPs are 
purchased through the Ministry of Health in govern-
ment procurement. In Macedonia, there is only one 
NRLs without any fees imposed on the patients. Un-
registered drugs may be purchased on condition 
there is no other adequate therapy for certain pati-
ents and that these drugs have already been sub-
mitted to the licensing procedure or have been in-
cluded in clinical research. 
 
Croatia - affordability  
 
The Croatian Law on Medicines is congruent to 
EU directives. The integral list of drugs for rare and 
serious diseases is being modulated and harmonised 
with the EU list. Medical expenses for the treatment 
of rare diseases are reimbursed by the state. The 
Croatian Ministry of Health is entitled to start an OD 
procedure. The national programme for RD predict-
ed an amount of 360,689,000 HRK (47,155,052 EUR) 
to be spent for their treatment for the period from 
2015 to 2020 (20).  
The representation of drugs which are being 
on NRLs relative to the complete number of regis-
tered OMPs in selected countries shows that in Ser-
bia more than a half of drugs is financially affordable 
comparing with Macedonia and Croatia where the 
financially affordable drugs make a third of complete 
registered OMP (Graph 2.). 
 
 
 
 
Graph 2. Total number of reimbursed OMPs (October 2014) 
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The financially most affordable OMPs with OD 
and MA, according to the first level of ATC classi-
fication were in group L – antineoplastics in all rese-
arched countries (Graph 3.). 
The financially most affordable OMPs without 
OD and MA according to the first level of ATC clas-
sification were in group L – antineoplastics, in all stu-
died countries (Graph 4.).  
 
 
 
 
 
Graph 3. Number of reimbursed OMPs with OD and MA by ATC code (October 2014) 
 
 
 
 
 
Graph 4. Number of reimbursed OMPs with MA and without OD by ATC code (October 2014) 
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Discussion 
 
The mutual comparison of the financially affor-
dable OMPs in Serbia, Macedonia and Croatia com-
paring with the complete number of registered drugs 
of this category represents the biggest financial af-
fordability of these drugs is in Serbia (54.24% of re-
gistered drugs), while it is smaller in Macedonia and 
Croatia (38.46%, 39.10% respectively), no matter 
that Macedonia has the smallest number of registe-
red drugs from the LODE while Croatia has all drugs 
from the LODE. This indicates to the fact that al-
though there is the problem with the lack of funds 
for financing the treatment of patients with RD, 
more than a half of registered OMPs can be refunded 
from NHIF. Despite the fact that in Croatia, a mem-
ber of the EU, a greater number of OMPs are registe-
red, they are not completely affordable to the pati-
ents. Macedonia has the smallest number of inhabi-
tants out of the three studied countries, which means 
that it also has the smallest number of patients from 
certain RD, which results in the lower total number 
of OMPs that are on the NRLs.There are very similar 
regulatory approaches in all three studied countries 
for MA for OMPs because they all came from the 
same health system and they harmonized the regula-
tions for drugs with the European directive. A couple 
of authors have been analysing the affordability of 
OMP in Serbia and other countries (Macedonia, Bul-
garia, Greece etc.) (21, 22). Besides, there were stu-
dies which compared the affordability of OMPs in 
other countries of the region, which represented that 
the affordability of drugs is different and subjected 
to dynamic changes (23). 
The study of Zlatareva et al.(21) have shown 
the registered OMPs in January 2013 in Serbia, while 
our study represented the growth of 10 drugs in Ser-
bia till October 2014. Comparing results of Zlatareva 
study with ours it is shown that the number of re-
funded drugs ( on the cost of health insurance) is 
marginally raising so as for the 1 drug with OD and 
MA and 3 drugs with the MA and without OD. 
Pavlovic et al. (22) investigated 4 drugs financially 
affordable in Serbia with OD and MA and 17 drugs 
with MA and without OD in July 2011, revealing that 
the number of affordable drugs is slowly raising in 
Serbia. Zlatareva et al. represented that there was 
only one drug with the OD and MA affordable in Ma-
cedonia in January 2013 while 14 drugs with the MA 
and without OD were on the NRLs (21). In 2014, our 
results suggested that the number of financially 
affordable drugs in Macedonia raised from one to 
two drugs with OD and MA, while 18 drugs without 
OD and MA were on the NRLs. 
 
Conclusion 
 
From the perspective of health politics, regu-
lative and legislative of OMPs within any country is 
different, the MA of ODs and the affordability thro-
ugh funds of health insurance is done in many dif-
ferent ways. 
Different accessibility of OMPs in all three 
countries could be explained with the different capa-
city and modality for financing the treatment of RDs, 
and national health policies criteria for refunding of 
these drugs. The affordability and accessibility of 
OMPs are generally the problem both in developed 
and undeveloped countries. Our study showed that 
RD patients in Croatia have better accessibility of 
drugs than patients in Serbia and Macedonia, but in 
Serbia the affordability is rather better because half 
of the registered OMPs is refunded.  
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Dostupnost lekova za retke bolesti (orfan lekovi, u EU regulativi koristi se izraz na 
engleskom Orphan medicinal products, OMP) igra važnu ulogu u tome da li će bolesnici sa 
retkim bolestima imati pristup efikasnoj i adekvatnoj terapiji. Ciljevi ovog rada su da se 
identifikuju razlike u pristupu bolesnika orfan lekovima u tri odabrane zemlje: Srbiji, Hrvatskoj 
i Makedoniji. Pristup orfan lekovima definisana je kao: tržišna pristupačnost (dostupnost) i 
priuštivost (finansijska pristupačnost). Analizirali smo legislativne zahteve u procesu stavljanja 
leka u promet i uradili komparaciju među posmatranim zemljama. Retrospektivnom studijom 
preseka poredili smo nacionalne liste lekova posmatranih zemalja i Listu orfan lekova u EU, za 
period od šest meseci (maj-oktobar 2014.). Od ukupno 179 OMP, koliko ih je u tom periodu 
bilo sa dozvolom za stavljanje u promet u EU, u Srbiji je bilo registrovano 59 (32,96%), u 
Makedoniji 52 (29,05%), dok su u Hrvatskoj učlanjenjem u EU svi registrovani lekovi postali 
tržišno dostupni. Međutim, dozvola za stavljanje u promet nije i garancija da bolesnik ima 
pristup datom leku, pa je samo 39,11% lekova sa dozvolom za stavljanje u promet bilo na 
listi lekova koje se refundiraju u Hrvatskoj (70 OMP). Broj lekova kojima bolesnici imaju 
pristup preko nacionalnih fondova zdravstvenog osiguranja u Srbiji i Makedoniji su manji (32 
OMP i 20OMP, respektivno), što čini da je priuštivost lekova u Srbiji tek 17,88% , a u 
Makedoniji 11,17% od liste orfan lekova u EU. Broj lekova, fizička i finansijska pristupačnost u 
analiziranim zemljama nije ista, dok je u Hrvatskoj bolesnicima dostupan najveći broj 
registrovanih lekova, u Srbiji se više od polovine registrovanih OMP može refundirati o trošku 
RFZO. Makedonija zbog manjeg broja stanovnika ima manji broj obolelih od RB, što rezultira 
manjim brojem OMP.   
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